Market Access: Pharma

Health Economics and Outcomes Research (HEOR) Strategy

Industry-leading research and strategy development

Alira Health provides a range of research and strategy solutions designed for commercial market success. We provide a host of advisory services, including
  • HEOR and evidence strategies
  • Reviews of global cost-effectiveness models and country adaptations
  • Budget impact and cost-effectiveness models
  • Patient-reported outcomes (PRO) strategies
  • Competitor analyses

Why choose Alira Health?

As your partner, we’ll work closely with you to uncover opportunities across the pharma industry, accelerate innovation, and deliver tomorrow’s standard of care. You’ll benefit from our:

  • Access to a diverse

    integrated team with deep industry expertise

  • Close collaboration

    with our regulatory and clinical

  • Specific, local insights

    as part of your larger, global strategy—a benefit of having market access teams in both the EU and U.S.

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Jean-François Ricci
Jean-François Ricci
Executive Vice President, Global Market Access
Our strong client partnerships allow us to deliver in-depth, customized strategies and access solutions—all designed to maximize product value across its full lifecycle.

Related News

Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
News January 24, 2024
Alira Health and AseBio Announce Market Access Mentoring Program for 2024
Alira Health and AseBio, the Spanish Bioindustry Association, are pleased to announce the 2024 edition of their market access mentoring program for AseBio members.
Biotech Market Access Spain Startups
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Case Studies January 18, 2024
Pharma Company Succeeds in Adding Medicine to World Health Organization Essential Medicines List
A pharma company with a blood disorder treatment needed support to submit a value dossier to the WHO to add a medicine to the Essential Medicines List.
Market Access Pharma
News January 18, 2024
Alira Health and Biocat Announce Startup Support Program for 2024
Alira Health and Biocat, a strategic stakeholder building the Catalan life sciences and ecosystem, partnered to foster Market Access for startups.
Market Access Startups
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.